Mitchall G. Clark, EVP & Chief R & QA Officer at Atara Biotherapeutics, Inc. (ATRA), sold 3,290 shares at $14.20 ($47K) on 2017-11-16, disclosed to the SEC on 2017-11-17.
Scheduled sale ($47k) by EVP & Chief R & QA Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ATRA | SELL | 2018-04-03 | $898K | — | Filing → |
| ATRA | SELL | 2018-03-28 | $3.8M | — | Filing → |
| ATRA | SELL | 2017-08-17 | $43K | — | Filing → |